Research programme: regulatory T cell therapy - TiGenix

Drug Profile

Research programme: regulatory T cell therapy - TiGenix

Alternative Names: Cx 911

Latest Information Update: 16 Mar 2012

Price : $50

At a glance

  • Originator Cellerix
  • Developer TiGenix
  • Class Cell therapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Autoimmune disorders; Inflammation

Most Recent Events

  • 16 Mar 2012 The programme is still in active development
  • 05 May 2011 Cellerix has been acquired by TiGenix
  • 19 Nov 2009 Preclinical trials in Inflammation in Spain (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top